United Laboratories International Holdings (HKG:3933) said its subsidiary's UBT251 drug received approval from the US Food and Drug Administration for a Phase II clinical trial targeting chronic kidney disease (CKD), according to a Monday filing with the Hong Kong Exchange.
Based on the preclinical obesity/diabetic nephropathy pharmacodynamic model, UBT251
demonstrated "significantly superior overall improvement effects on renal urinary albumin and
other related renal injury markers and histopathology than Semaglutide," United Laboratories said.
UBT251, developed by United Laboratories subsidiary The United Bio-Technology (Hengqin), received clinical trial authorization in China in January for the same indication.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。